deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT02587650

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma

Sponsor: University of California, San Francisco

Conditions ALK Fusion Protein Expression BRAF wt Allele Invasive Skin Melanoma MET Fusion Gene Positive NRAS wt Allele NTRK1 Fusion Positive NTRK2 Fusion Positive NTRK3 Fusion Positive RET Fusion Positive ROS1 Fusion Positive Stage III Cutaneous Melanoma Stage IIIA Cutaneous Melanoma Stage IIIB Cutaneous Melanoma Stage IIIC Cutaneous Melanoma Stage IV Cutaneous Melanoma
Interventions Capmatinib Ceritinib Entrectinib Laboratory Biomarker Analysis Regorafenib
Updated 12 times since 2017 Last updated: Jan 14, 2020 Started: Mar 26, 2015 Primary completion: Jul 12, 2018 Completion: Jul 12, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding

Other terminated trials from University of California, San Francisco

See all terminations from University of California, San Francisco

This PHASE2 trial investigates ALK Fusion Protein Expression and BRAF wt Allele and is currently terminated or withdrawn. University of California, San Francisco leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshotActive Not Recruiting~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotRecruiting~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotRecruiting~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshotCompleted~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  3. Jun 2019 — Feb 2020 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  5. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  6. Feb 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations